We hypothesized that oxybutynin (cholinergic agent in successful OSA pharmacotherapy) is an effective MR antagonist at the HMN and characterized its efficacy with other antagonists. This evidence concerns the gene NR3C2 and obstructive sleep apnea syndrome.